Clinical Trials Browser

Breast Neoplasms

NCT04059484 2026-02-24

AMEERA-3

Phase 2 Terminated

367 enrolled 30 charts

Breast

Breast Cancer Metastatic

NCT04191382 2025-09-18

AMEERA-4

Phase 2 Terminated

105 enrolled 16 charts

Breast

Breast Neoplasms

NCT04478266 2025-09-11

AMEERA-5

Phase 3 Terminated

1,068 enrolled 21 charts

Breast

Breast Neoplasms

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast

Breast Neoplasms

NCT01897441 2024-12-24

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

Phase NA Terminated

31 enrolled 11 charts

Breast

Breast Neoplasms

NCT01296555 2024-07-31

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Phase 1 Terminated

674 enrolled 55 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT03874325 2022-05-31

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Phase 2 Terminated

17 enrolled 10 charts

Breast

Breast Neoplasms

NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

Phase 2 Terminated

3 enrolled 4 charts

Breast

Breast Neoplasms

NCT01499160 2022-02-11

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

Phase 2 Terminated

7 enrolled 6 charts

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT02907918 2021-09-29

PALTAN

Phase 2 Terminated

26 enrolled 8 charts

Breast

Breast Neoplasms

NCT00880009 2021-09-27

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

Phase 2 Terminated

16 enrolled 6 charts

Breast

Breast Neoplasms

NCT00461773 2021-03-16

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

Phase 2 Terminated

5 enrolled 7 charts

Breast

Breast Neoplasms

NCT00796107 2020-11-13

A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

Phase 2 Terminated

6 enrolled 5 charts

Breast

Breast Neoplasms

NCT01225172 2020-08-11

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

Phase 2 Terminated

77 enrolled 11 charts

Breast

Breast Neoplasms

NCT03050398 2020-05-28

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Phase 3 Terminated

8 enrolled 4 charts

BreastEndocrine

Breast Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT02115048 2019-12-26

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

Phase 2 Terminated

44 enrolled 15 charts

Breast

Breast Neoplasms

NCT00414076 2018-11-20

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

Phase 2 Terminated

9 enrolled 7 charts

GynecologicSarcoma

Leiomyosarcoma, Uterine Neoplasms

NCT01484041 2018-02-09

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

Breast

Breast Neoplasms

NCT00375752 2017-06-26

FEMZONE

Phase 4 Terminated

168 enrolled 11 charts

Breast

Breast Neoplasms

NCT00549822 2017-03-22

Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer

Phase 2 Terminated

3 enrolled 8 charts

BreastGenitourinary

Medullary cystic kidney disease 1, Breast Neoplasms

NCT00573755 2016-02-05

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

Phase 2 Terminated

4 enrolled 8 charts

Breast

Breast Neoplasms

NCT01919229 2016-01-01

MONALEESA-1

Phase 2 Terminated

14 enrolled 7 charts

Breast

Breast Neoplasms

NCT01368263 2015-04-03

Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

Phase 2 Terminated

8 enrolled 5 charts

Breast

Breast Neoplasms

NCT01430585 2014-08-12

Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer

Phase 2 Terminated

14 enrolled 5 charts

Breast

Breast Neoplasms

NCT01205685 2012-09-11

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

Phase 2 Terminated

11 enrolled 9 charts

Breast

Hormone-sensitive Metastatic Breast Cancer

NCT00499681 2012-08-10

PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE

Phase 2 Terminated

6 enrolled 8 charts

Breast

Breast Neoplasms

NCT00611715 2012-08-09

Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

Phase 2 Terminated

48 enrolled 11 charts

Breast

Breast Neoplasms

NCT00505661 2012-04-18

Letrozole in Patients With Ovarian Tumors

Phase 2 Terminated

16 enrolled 3 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Clinical Trials

GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients

AMEERA-3

AMEERA-4

AMEERA-5

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Chemotherapy Before Surgery and Tissue Sample Collection in Patients With Stage IIA-IIIC Breast Cancer

A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Phase II Study of Everolimus Beyond Progression

Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer

PALTAN

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer

A Study of R1507 in Combination With Letrozole in Postmenopausal Women With Advanced Breast Cancer

Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors

A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib

Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole Alone

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

FEMZONE

Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer

Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer

MONALEESA-1

Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE

Ph II Letrozole + OSI-774 (Tarceva) in Post-menopausal, w/ ER and/or PR-positive Met Breast Cancer.

Letrozole in Patients With Ovarian Tumors